Nektar Therapeutics
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
455 Mission Bay Blvd S, San Francisco, C...Phone Number
(415) 482-5300Website
www.nektar.comRevenue
$55.6 MillionStock Symbol
NKTRIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company focused on the research and development of innovative medicines designed to address serious unmet medical needs. The company is known for its expertise in advanced drug design and polymer conjugate technology, which it applies to enhance the effectiveness and safety of therapeutic compounds. Nektar Therapeutics concentrates on areas such as immunology, oncology, and autoimmune diseases, aiming to create treatments that modulate the immune system in precise and durable ways. Through a combination of in-house research and strategic collaborations, the company seeks to translate scientific insights into novel therapies that can improve patient outcomes.Explore more
Nektar Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nektar Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Nektar Therapeutics
Check if Nektar Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Nektar Therapeutics is spiking on competitors!
Nektar Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Nektar Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Nektar Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Nektar Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Nektar Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Nektar Therapeutics
Compare insights from companies similar to Nektar Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$216.8M
51-200
Public
$1.1B
1991
SK
Stephen KetchumExecutive VP & President, Research & Development & Chief Scientific Officer
Company Profile Activity
Activity Insights
Nektar Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nektar Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nektar Therapeutics.
Nektar Therapeutics financials insights
Gather financial insights about Nektar Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Debt
$125M
2013
Corporate Investment
$25M
2014
Stock Offering
$117M
2015
Debt
$250M
2016
Corporate Investment
$20M
Stock Offering
$175.5M
2018
Share Placement
$850M
2024
Share Placement
$30M
Nektar Therapeutics Tech Stack
A closer look at the technologies used by Nektar Therapeutics
See more technologies
Most Recent Scoops
Hiring Plans
Nektar Therapeutics has more open roles in Operations than it has had at any time in the past 12 months.
Hiring Plans
Open Position
Open Position
Open Position
Open Position
Nektar Therapeutics News & Media
What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock
Nektar Therapeutics (NASDAQ:NKTR) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 11, Wedbush analyst Martin Fan decreased the price target on Nektar Therapeutics (NASDAQ:NKTR) from $95 to $80 while reiterating a Neutral rating. This revision is followed by the recent corporate earnings report, where Nektar has reaffirmed […]Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 11,900 shares of its common...Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York
SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York. 2026 Jefferies Global Healthcare Conference...Interim CFO at Nektar Therapeutics (NKTR) files initial Form 3 ownership report - Stock Titan
Interim CFO Linda M. Rubinstein files an initial Form 3 for Nektar Therapeutics, listing her as an officer with no reported stock purchases, sales or exercises.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nektar Therapeutics
Sign Up For FreeTo access detailed company insights
Nektar Therapeutics is a biopharmaceutical company focused on the research and development of innovative medicines designed to address serious unmet medical needs. The company is known for its expertise in advanced drug design and polymer conjugate technology, which it applies to enhance the effectiveness and safety of therapeutic compounds. Nektar... Read More
